Interestingly, many of these cellular targets have also been highlighted as novel druggable targets for AD treatment by the US National Institute on Aging-funded AMP AD and TREAT-AD consortiums, including CYP19A1, LXRs, p38 MAPKs, NR3C1, and SYK.124. This evidence concerns the gene SYK and Alzheimer disease.